Loading patent…
AssigneeArena Pharmaceuticals, Inc.
InventorsBradley Teegarden, Yifeng Xiong, Sonja Strah-Pleynet, Honnappa Jayakumar, Peter I. Dosa, Konrad Feichtinger, Martin Casper, Juerg Lehmann, Robert M. Jones, David J. Unett, Jin Sun Karoline Choi
Estimating the term…
The present invention relates to certain 3-phenyl-pyrazole derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the 5-HT2A serotonin receptor. Compounds and pharmaceutical compositions thereof are directed to methods useful in the treatment of platelet aggregation, coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, atrial fibrillation, reducing the risk of blood clot formation, asthma or symptoms thereof, agitation or a symptom, behavioral disorders, drug induced psychosis, excitative psychosis, Gilles de la Tourette's syndrome, manic disorder, organic or NOS psychosis, psychotic disorder, psychosis, acute schizophrenia, chronic schizophrenia, NOS schizophrenia and related disorders, and sleep disorders, sleep disorders, diabetic-related disorders, progressive multifocal leukoencephalopathy and the like. The present invention also relates to the methods for the treatment of 5-HT2A serotonin receptor mediated disorders in combination with other pharmaceutical agents administered separately or together.
A method for treating a 5-HT2A mediated disorder selected from the group consisting of coronary artery disease, myocardial infarction, transient ischemic attack, angina, stroke, and atrial fibrillation in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound having the structure
A method for treating a condition associated with platelet aggregation selected from the group consisting of claudication, peripheral artery disease, vasoconstriction, vasospasm, arterial occlusion, thrombosis, and stroke in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound having the structure
A method for reducing the risk of blood clot formation in an angioplasty or coronary bypass surgery individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound having the structure
A method for reducing the risk of blood clot formation in an individual suffering from atrial fibrillation, comprising administering to said individual in need thereof a therapeutically effective amount of a compound having the structure
A method for treating a sleep disorder in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound having the structure
A method for treating a sleep disorder in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound having the structure
A method for treating progressive multifocal leukoencephalopathy in an individual comprising administering to said individual in need thereof a therapeutically effective amount of a compound having the structure
A method for treating hypertension in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound having the structure
A method for treating pain in an individual comprising administering to the individual in need thereof a therapeutically effective amount of a compound having the structure
Dependencies are inferred from the claim text.